Article
MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor.
Lung cancer (Amsterdam, Netherlands) - 1 Dec 2015
Togashi Yosuke, Mizuuchi Hiroshi, Tomida Shuta, Terashima Masato, Hayashi Hidetoshi, Nishio Kazuto, Mitsudomi Tetsuya
Abstract excerpt
BACKGROUND: MET splice site mutations resulting in an exon 14 deletion have been reported to be present in about 3% of all lung adenocarcinomas. Patients with lung adenocarcinoma and a MET splice site mutation who have responded to MET inhibitors have been reported. The CRISPR/Cas9 system is a recently developed genome-engineering tool that can easily and rapidly cause small insertions or deletions. MATERIALS AND...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.